Endostatin and ST2 are predictors of pulmonary hypertension disease course in infants.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
12
10
2019
accepted:
17
04
2020
revised:
16
03
2020
pubmed:
6
5
2020
medline:
26
8
2021
entrez:
6
5
2020
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) is a common comorbidity of cardiopulmonary disease. Endostatin, an inhibitor of angiogenesis, is elevated in neonates with lung disease. ST2 is a heart failure biomarker correlated with PH in adults. We hypothesized that these biomarkers may be useful in diagnosing PH and categorizing its severity in infants. Endostatin, ST2, and NT-proBNP plasma concentrations from 26 infants with PH and 21 control infants without PH were correlated with echocardiographic and clinical features using regression models over time. Endostatin, ST2, and NT-proBNP concentrations were elevated in PH participants versus controls (p < 0.0001). Endostatin was associated with right ventricular dysfunction (p = 0.014), septal flattening (p = 0.047), and pericardial effusion (p < 0.0001). ST2 concentrations predicted right to left patent ductus arteriosus flow (p = 0.009). NT-proBNP was not associated with PH features. Endostatin and ST2 concentrations were associated with echocardiographic markers of worse PH in infants and may be better predictors than existing clinical standards.
Identifiants
pubmed: 32366869
doi: 10.1038/s41372-020-0671-8
pii: 10.1038/s41372-020-0671-8
pmc: PMC7578107
mid: NIHMS1585845
doi:
Substances chimiques
Biomarkers
0
Endostatins
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1625-1633Subventions
Organisme : NICHD NIH HHS
ID : K12 HD000850
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL114800
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL135114
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120:1260–9.
doi: 10.1542/peds.2007-0971
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53:1–18.
Warburton D. Overview of lung development in the newborn human. Neonatology. 2017;111:398–401.
doi: 10.1159/000458465
Kulik TJ, Austin ED. Pulmonary hypertension’s variegated landscape: a snapshot. Pulm Circ. 2017;7:67–81.
doi: 10.1177/2045893216686930
Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics. 2008;121:317–25.
doi: 10.1542/peds.2007-1583
Ten Kate CA, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr. 2015;174:1267–75.
doi: 10.1007/s00431-015-2619-0
Behere S, Alapati D, McCulloch MA. Screening echocardiography and brain natriuretic peptide levels predict late pulmonary hypertension in infants with bronchopulmonary dysplasia. Pediatr Cardiol. 2019;40:973–9.
doi: 10.1007/s00246-019-02100-8
Janer J, Andersson S, Haglund C, Lassus P. Pulmonary endostatin perinatally and in lung injury of the newborn infant. Pediatrics. 2007;119:e241–6.
doi: 10.1542/peds.2005-3039
Kim DH, Kim HS. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension. Neonatology. 2014;106:55–61.
doi: 10.1159/000358374
Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;191:208–18.
doi: 10.1164/rccm.201409-1742OC
Pascual-Figal DA, Garrido IP, Blanco R, Minguela A, Lax A, Ordonez-Llanos J, et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg. 2011;92:2118–24.
doi: 10.1016/j.athoracsur.2011.07.048
Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. 2015;115 7 Suppl:3b–7b.
doi: 10.1016/j.amjcard.2015.01.034
Chida A, Sato H, Shintani M, Nakayama T, Kawamura Y, Furutani Y, et al. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Circulation J. 2014;78:436–42.
doi: 10.1253/circj.CJ-13-1033
Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594–607.
doi: 10.1016/j.yexcr.2005.11.015
Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol. 2011;30:83–92.
doi: 10.1016/j.matbio.2010.11.001
Janer J, Andersson S, Kajantie E, Lassus P. Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics. 2009;123:1142–6.
doi: 10.1542/peds.2008-1339
Richter AG, McKeown S, Rathinam S, Harper L, Rajesh P, McAuley DF, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax. 2009;64:156–61.
doi: 10.1136/thx.2008.102814
Liu J, Wang W, Wang L, Chen S, Tian B, Huang K, et al. IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1alpha and VEGF expression in vascular endothelial cells. EBioMedicine 2018;33:196–210.
doi: 10.1016/j.ebiom.2018.06.003
Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009;2:311–9.
doi: 10.1161/CIRCHEARTFAILURE.108.833707
Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem. 2015;48:1337–40.
doi: 10.1016/j.clinbiochem.2015.08.007